Page 1

01 Financial Summary for the group KSEK Profit / loss before tax Total assets Earnings per share before and after dilution ( SEK ) Cash and cash equivalents as per period end Equity ratio as per period end Significant Events Significant events during the first quarter of 2021 ● Cyxone reported first Covid - 19 patient screened in Phase 2 clinical trial of Rabeximod . Interim Report Q1 2021 January 1 - March 31 Tara Heitner , CEO Phone : +46 ( 0 ) 70 781 88 08 E - mail : tara.heitner@cyxone.com CYXONE ● Cyxone AB ( Corp. reg . no . 559020-5471 ) Q1 , 2021 -8 612 62 482 -0,15 47 268 93,6 % Q1 , 2020 Significant events after the end of the period World leading rheumatology authority Professor Costantino Pitzalis collaborates with Cyxone on Rabeximod Phase 2b study . -10 197 65 012 -0,21 52 877 The group was formed on 30 July 2019 when Cyxone AB formed the subsidiary Cyxone Switzerland AG . The Group's Financial reports are prepared in accordance with International Financial Reporting Standards ( IFRS ) , as adopted by the EU . The parent company applies the Swedish Annual Accounts Act ( 1995 : 1554 ) and RFR 2 Accounting for Legal Entities , as the Group applies IFRS . The interim report for the parent company has been prepared in accordance with Chapter 9 of the Swedish Annual Accounts Act , Interim Report . Details of the Group's and parent company's accounting principles under IFRS are available on Cyxone's website : cyxone.com/investorrelations/ . 94,7 % This is a translation of the original Swedish version of the interim report . In case of any discrepancy between this translation and the Swedish original , the latter shall prevail . This information is such information as Cyxone AB ( publ ) is obliged to make public pursuant to the Swedish Securities Markets Act . The information was submitted for publication , through the agency of the contact person set out above , at 08.30 a.m. CEST on 12 May 2021 . Interim Report Q1 2021 | 1